Hatice Yesim Karasulu | Cell Differentiation Processes | Best Innovation Award

Prof. Dr. Hatice Yesim Karasulu | Cell Differentiation Processes | Best Innovation Award

Prof. Dr. Hatice Yesim Karasulu , Ege University, Faculty of Pharmacy, Pharmaceutical Technology , Turkey

Prof. Dr. H. Yeşim Karasulu is a distinguished academic and researcher in pharmaceutical technology, based at Ege University in Turkey. With a career spanning decades, she earned her Ph.D. in Pharmaceutical Technology from Ege University, where she became an Associate Professor in 2006 and a full Professor in 2011. Prof. Karasulu has held numerous positions, including consultant for the Ege University Center for Drug Research & Development (ARGEFAR) and member of the pharmaceutical technology commission at Turkey’s Ministry of Health from 2006 to 2024. She has contributed extensively to drug delivery systems and pharmaceutical formulations, especially focusing on colloidal drug delivery. Over the years, she has published over 50 research papers, authored five book chapters, and is the holder of two patents related to nano-drug delivery systems. Her work has advanced both academic knowledge and pharmaceutical industry practices.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Extensive Research Experience: Prof. Dr. H. Yeşim Karasulu has an exceptional track record with more than 50 publications, multiple patents, and ongoing research projects. Her innovative work in colloidal drug delivery systems, including liposomes, nano/microparticles, nano/microemulsions, and self-emulsifying drug delivery systems (SEDDS), positions her as a leading researcher in the pharmaceutical field.
  2. High Impact and Collaboration: Her research is widely cited with an H-index of 16 (WoS) and 18 (Scopus). She has collaborated with prestigious institutions such as the University of Vienna and the Aristotle University of Thessaloniki, further enhancing the global impact of her work.
  3. Patent and Industry Collaboration: Prof. Karasulu’s research has led to two patents and several patent applications, showcasing the practical and commercial value of her innovations. Additionally, her collaborative efforts with the pharmaceutical industry in developing drug delivery systems highlight her ability to bridge academia and industry, enhancing the potential for real-world applications.
  4. Ongoing Research Projects: Prof. Karasulu is involved in multiple research projects, both academic and industry-sponsored, demonstrating her continuous commitment to advancing pharmaceutical sciences. Her ongoing projects include drug delivery systems targeting specific organs and improving drug bioavailability and stability.
  5. Awards and Recognition: Prof. Karasulu’s achievements are recognized through awards such as the Ege ArGe First Prize and the Ege ArGe Innovation Award, confirming the innovative nature of her research.

Areas for Improvement:

  1. Broader International Visibility: While Prof. Karasulu has a strong track record within her field, expanding her international visibility by increasing collaborations with leading global pharmaceutical companies could further enhance the global reach and impact of her innovations.
  2. Diversity of Published Works: Though Prof. Karasulu has an impressive number of publications, exploring opportunities for publication in high-impact journals outside her primary research focus could enhance her visibility in other areas of pharmaceutical sciences.
  3. Focus on Translational Research: While there is a strong emphasis on preclinical studies and formulation development, further focus on clinical trials and commercialization of her innovations could enhance the practical application of her work, especially with regard to regulatory approval processes for new drug delivery systems.

Education:

Prof. Dr. H. Yeşim Karasulu pursued her academic studies at Ege University in Izmir, Turkey. She completed her Bachelor’s degree in Pharmacy at the Faculty of Pharmacy before obtaining a Ph.D. in Pharmaceutical Technology from the same institution. Her education continued with postdoctoral research at the University of Vienna, focusing on Pharmaceutical Technology and Biopharmaceutics under the guidance of Prof. Dr. Franz Gabor. This international research experience allowed her to expand her expertise in colloidal drug delivery systems, setting the foundation for her career as a researcher. Throughout her education, Prof. Karasulu’s work has concentrated on the development of drug delivery systems, with an emphasis on enhancing the bioavailability and targeting of drugs using innovative methods like liposomes, nano/microparticles, and microemulsions. Her academic background has enabled her to contribute significantly to both research and industry practices in pharmaceutical sciences.

Experience:

Prof. Dr. H. Yeşim Karasulu has a distinguished career in both academia and the pharmaceutical industry. She began her academic career as a faculty member at Ege University, where she progressed from an Assistant Professor to a full Professor in the Department of Pharmaceutical Technology. Additionally, she has been an active consultant at the Ege University Center for Drug Research & Development (ARGEFAR) since 2011. Prof. Karasulu also served as a member of the Pharmaceutical Technology Commission at the Turkish Ministry of Health’s Pharmaceuticals and Medical Devices Agency between 2006 and 2024, helping shape national pharmaceutical policies. Her extensive research has led to breakthroughs in nano-drug delivery systems, contributing to the development of two patents and several industry projects. She has worked on numerous national and international projects focusing on drug formulation, bioavailability enhancement, and targeting systems, particularly for cancer therapy and chronic diseases.

Research Focus:

Prof. Dr. H. Yeşim Karasulu’s research primarily focuses on the development and evaluation of advanced colloidal drug delivery systems. Her work spans liposomes, nano/microparticles, nano/microemulsions, and self-emulsifying drug delivery systems (SEDDS). These innovative systems aim to enhance the bioavailability, stability, and targeted delivery of pharmaceutical compounds. Prof. Karasulu has led several high-impact research projects funded by both national (TUBİTAK) and international bodies, such as the European Union. Her research is dedicated to improving the therapeutic efficacy of drugs, particularly in challenging areas like cancer treatment and chronic diseases. Prof. Karasulu’s work is closely aligned with real-world applications, as evidenced by her ongoing collaboration with the pharmaceutical industry to bring new drug delivery systems to market. Her goal is to create formulations that not only improve patient outcomes but also contribute to the overall advancement of pharmaceutical technology.

Publications Top Notes:

  1. “Degradation and gastrointestinal stability of nitrofurantoin in acidic and alkaline media” 📉💊
  2. “Sustained-release dosage form of nitrofurantoin: Part 1. Preparation of microcapsules and in vitro release kinetics” 💊🔬
  3. “33 factorial design-based optimization of the formulation of nitrofurantoin microcapsules” 🔬📊
  4. “In vitro-in vivo correlations of nitrofurantoin matrix tablet formulation” 💊⚖️
  5. “A New In Vitro/In Vivo Kinetic Correlation Method for Nitrofurantoin Matrix Tablet Formulations” 🧪💡
  6. “Sustained release bioadhesive effervescent ketoconazole microcapsules tabletted for vaginal delivery” 💊💥
  7. “Different geometric shaped hydrogel theophylline tablets: Statistical approach for estimating drug release” 💊📐
  8. “Extended release lipophilic indomethacin microspheres: formulation factors and mathematical equations fitted drug release rates” 💊🔢
  9. “Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets” 🧪📊
  10. “Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida Albicans” 💊🦠
  11. “Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line” 🔬🧪
  12. “In vitro permeation of diclofenac sodium from novel microemulsion formulations through rabbit skin” 💊🐇
  13. “Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line” 🔬💉
  14. “Transdermal delivery of diclofenac sodium through rat skin from various formulations” 💊🦷
  15. “Controlled release of methotrexate from W/O microemulsion and its in vitro anti-tumor activity” 🧪💥

Conclusion:

Prof. Dr. H. Yeşim Karasulu is a highly deserving candidate for the Best Innovation Award. Her groundbreaking research in colloidal drug delivery systems has significantly contributed to advancements in pharmaceutical sciences. With numerous publications, patents, and collaborations, her work not only pushes the boundaries of scientific research but also has a profound impact on drug development. By focusing on broader international collaborations and further developing translational research strategies, Prof. Karasulu’s contributions to the pharmaceutical industry and academic community will continue to grow, solidifying her place as a leader in innovation.

 

 

Chunli Ma | Stem Cell Research | Best Researcher Award

Ms. Chunli Ma | Stem Cell Research | Best Researcher Award

Ms. Chunli Ma  , Shandong Provincial Hospital Affiliated to Shandong First Medical University , China

Chunli Ma is a Master’s student at Shandong Provincial Hospital Affiliated with Shandong First Medical University in China. With a strong background in Optometry and Vision Science, Ma has expanded into Ophthalmology for her graduate studies. She possesses a deep understanding of ocular disorders and the corresponding diagnostic and treatment protocols. She is passionate about cellular and molecular experimentation, specializing in animal models for scientific research. Her expertise extends to experimental techniques that offer innovative solutions for eye injury and healing. Chunli’s work aims to improve corneal repair, reduce scarring, and enhance treatment outcomes for ocular diseases through advanced therapeutic approaches, including stem cell therapy and specialized eye drops.

Publication Profile:

Orcid

Strengths for the Award:

Chunli Ma is a promising researcher with a strong foundation in both clinical ophthalmology and experimental techniques. Her academic background in Optometry and Vision Science, along with her specialized focus on Ophthalmology, positions her as an emerging leader in the field. Ma’s contributions to the understanding and treatment of corneal injuries, particularly her work on exosomes derived from adipose mesenchymal stem cells and antibacterial eyedrops, have significant therapeutic potential. The formulation of exosomes into eyedrops to aid in rapid corneal healing and prevent scarring, along with the development of multifunctional eyedrops for treating bacterial keratitis, showcases her innovative approach to solving complex clinical challenges. Her ability to translate laboratory research into potential clinical applications is commendable. Moreover, her publications in well-regarded journals and ongoing involvement in impactful research add to her eligibility for the Best Researcher Award.

Areas for Improvement:

While Chunli Ma’s work demonstrates great potential, there are areas where she could continue to develop. Expanding her research to a broader range of ocular conditions beyond corneal injury and keratitis could make her work even more influential across various ophthalmic fields. Additionally, seeking more collaborations with interdisciplinary teams, such as those focusing on the genetic and molecular mechanisms of ocular diseases, could provide deeper insights and enhance her ability to tackle more complex issues. Although she has made valuable contributions to scientific publications, continuing to increase the number and impact of her published papers, especially in top-tier journals, will further solidify her reputation in the scientific community. Gaining experience in patent applications and commercialization of her research could also help bridge the gap between laboratory findings and real-world clinical application.

Education:

Chunli Ma completed her undergraduate degree in Optometry and Vision Science, where she gained foundational knowledge in ocular health and vision correction. Building on this, she pursued a Master’s degree in Ophthalmology, which allowed her to specialize in clinical and experimental ophthalmic research. Her academic journey includes hands-on research in cell biology, molecular techniques, and experimental models to address common ocular disorders, particularly in corneal injury repair. Chunli’s academic training has not only refined her diagnostic skills but also equipped her with cutting-edge knowledge in treatment and therapeutic strategies. Her graduate work bridges practical clinical care with advanced research, focusing on cellular regeneration, stem cell treatments, and tissue healing in the eye. This robust academic background underpins her ongoing commitment to advancing ophthalmic medicine through innovative scientific inquiry and applied research in the field of corneal injury and wound healing.

Experience:

Chunli Ma’s academic journey has been bolstered by hands-on experience in both clinical ophthalmology and cellular research. Her work in experimental ophthalmology has focused on the use of adipose mesenchymal stem cells for corneal repair, creating new methodologies for promoting healing and reducing scarring. She has demonstrated expertise in animal model management and experimentation, gaining insights into complex biological processes affecting eye injuries. Ma has contributed to the development of novel treatments, including multifunctional eye drops for both bacterial keratitis and corneal trauma. Her research findings have important clinical implications, directly informing therapeutic strategies for ocular health. Additionally, Ma’s experience includes publishing scientific articles, with a growing portfolio in well-regarded journals. This combination of clinical knowledge, experimental research, and hands-on technique has allowed her to make valuable contributions to ophthalmic science, particularly in terms of innovative solutions for corneal injury and healing.

Research Focus:

Chunli Ma’s research focus is centered on the mechanistic modulation of corneal injury and wound healing. She investigates the potential of stem cell-derived exosomes in promoting the regeneration of corneal tissues, with a particular interest in their role in reducing scarring after trauma. Her work delves into advanced therapeutic applications, such as multifunctional eye drops containing composite antibacterial and healing properties for the treatment of Pseudomonas aeruginosa keratitis. By targeting the underlying molecular and cellular mechanisms of corneal repair, Ma aims to offer innovative solutions for treating corneal injuries and infections. Her research also explores the impact of wound size and location on the prognosis of penetrating ocular injuries, offering a more nuanced approach to patient care. Chunli’s focus on the development of cutting-edge materials and therapies for ophthalmic applications promises significant advances in clinical practice, particularly for patients with challenging corneal conditions.

Publications Top Notes:

  1. Exosomes derived from adipose mesenchymal stem cells promote corneal injury repair and inhibit the formation of scars by anti-apoptosis 📑🧬
  2. Wound size and location affect the prognosis of penetrating ocular injury 👁️‍🗨️🩹
  3. Potential role of ARG1 c.57G > A variant in Argininemia 🔬🧬

Conclusion:

Chunli Ma’s research reflects an excellent blend of clinical expertise and innovative scientific inquiry. Her work has already made notable contributions to improving the treatment of ocular injuries, particularly in corneal healing and bacterial keratitis. With a clear focus on translational research, she has demonstrated the potential for significant advancements in ophthalmic treatments. Given her ongoing dedication to advancing ophthalmology through novel therapeutic approaches, Chunli Ma is undoubtedly a strong candidate for the Best Researcher Award. With continued growth in her research, collaboration efforts, and scholarly output, she has the potential to make even greater strides in the field of ophthalmology and regenerative medicine.